Fitabeo Therapeutics, a clinical-stage specialty pharmaceutical company spun out from the University of Strathclyde, has secured a new patent in Japan for its innovative drug delivery technology.
SpherionexT is a cutting-edge controlled-release film technology designed to enhance the efficacy, safety, and patient compliance of various therapeutic agents by improving the precision and control of drug release within the body.
Revolutionise treatment
It is hoped that the technology will revolutionise the treatment landscape for a variety of chronic and acute medical conditions.
Director Of Innovation & Industry Engagement at the University of Strathclyde, Meryl Levington, said: “We are delighted that the Japanese patent for the oral thin film technology developed at the University, has been granted.
We are hopeful that the other patent territories will follow suit, increasing investor attractiveness to ultimately speed up the process of bringing new medicines to market.
Innovative technology
Professor Alex Mullen, Chief Scientific Officer of Fitabeo Therapeutics, said: “We are incredibly proud to have received this patent, which underscores our commitment to innovation and excellence in drug delivery systems.
“This recognition validates our innovative technology and reinforces our commitment to advancing pharmaceutical research. SpherionexT has the potential to significantly improve patient outcomes and set new standards in the treatment of various diseases.
“This patent is a testament to the hard work and dedication of our research and development team and reflects our collaboration with the University of Strathclyde to deliver impactful medicines.”
The company is also actively exploring partnerships and licensing opportunities to bring the potentially transformative technology to market.